Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13082369 | 0.77 | KDM4E (0.70) | ALDH1A1MEN1KMT2AHTTKDM4E | |
| SCHEMBL1976397 | 0.71 | POLB (0.47) | ALDH1A1MEN1KMT2AHTTKDM4E | |
| SCHEMBL3756464 | 0.70 | ALDH1A1 (0.37) | ALDH1A1KDM4ESMN1; SMN2MAPTGRM2 | |
| SCHEMBL1969780 | 0.69 | POLB (0.51) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL6514641 | 0.69 | MEN1 (0.43) | ALDH1A1MEN1KMT2AHTTKDM4E | |
| SCHEMBL1972746 | 0.68 | MEN1 (0.47) | ALDH1A1MEN1KMT2AHTTKDM4E | |
| SCHEMBL1967350 | 0.66 | KDM4E (0.54) | ALDH1A1MEN1KMT2AHTTKDM4E | |
| SCHEMBL1987167 | 0.65 | EGLN1 (0.42) | ALDH1A1MEN1KMT2AHTTKDM4E | |
| SCHEMBL25427616 | 0.65 | HTT (0.39) | ALDH1A1MEN1KMT2AHTTKDM4E | |
| SCHEMBL13619715 | 0.65 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2AHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038286-B1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| CN-102584649-A | Pyrro[1,2-b]pyridazinone compounds | ANADYS PHARMACEUTICALS INC | 2012-07-18 | — | — | CN | disclosed |
| CN-101501039-B | Pyrrolo [1,2-b ] pyridazinone compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-02-22 | — | — | CN | disclosed |
| US-7842838-B2 | Pyrro[1,2-b]pyridazinone intermediates | ANADYS PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090312570-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC (US) | 2009-12-17 | — | — | US | disclosed |
| US-7582754-B2 | For treating hepatitis C virus infections; polymerase inhibitors | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| CN-101501039-A | Pyrrolo [1, 2-b ] pyridazinone compounds | ANADYS PHARMACEUTICALS INC (US) | 2009-08-05 | — | — | CN | disclosed |
| US-20090105473-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-7462611-B2 | inhibitor of HCV NS5B polymerase; to treat infections caused by hepatitis C virus; 3-(1,1-Dioxo-1,4-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-4-hydroxy-1-(3-methyl-butyl)-pyrrolo[1,2-b]pyridazin-2-one | ANADYS PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080031852-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312570-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, CYP4B1, CYP1B1 | ALDH1A1 648/4885MEN1 2777/4885KMT2A 4499/4885 |
| US-20080031852-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, CYP4B1, CYP1B1 | ALDH1A1 648/4885MEN1 2777/4885KMT2A 4499/4885 |
| US-20090105473-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, CYP4B1, CYP1B1 | ALDH1A1 648/4885MEN1 2777/4885KMT2A 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.